Celestica Work in process decreased by 3.3% to $139.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.2%, from $113.60M to $139.90M. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $106.60M | $113.60M | $132.70M | $154.70M | $144.60M | $139.90M |
| QoQ Change | — | +6.6% | +16.8% | +16.6% | -6.5% | -3.3% |
| YoY Change | — | — | — | — | +35.6% | +23.2% |
| % of Inventories | 6.1% | 6.4% | 6.9% | 7.6% | 6.6% | 5.2% |
| Share Change | — | +0.3pp | +0.6pp | +0.6pp | -0.9pp | -1.4pp |